The company aimed to perform a comprehensive analysis of camelid germline immunoglobulin V gene repertoires and assess homology to human counterparts. Manual analysis of thousands of sequences is time-consuming and prone to error.
We mined camelid genomes, analysed homology with humans and streamlined immunoinformatics to accelerate antibody discovery.
Purpose-built computational tools reduce the barriers to antibody discovery. Automating sequence analysis accelerates therapeutic development and opens new avenues in immuno-biotech.
Let’s discuss how we can turn your data into real scientific impact.
Contact us >
BioLizard has been named “Bioinformatics Innovation of the Year” in the 2025 BioTech Breakthrough Awards. The honor spotlights Bio|Verse® Navigator, a visual analytics workspace that unifies complex R&D data so scientists can decide faster, with confidence.
Bioinformatics pipelines break for the smallest reasons: package updates, shifting dependencies, or “it only works on my machine.” This post explains why experienced software engineers and DevOps practices (Git, CI/CD, IaC) are essential to keep workflows reproducible, stable, and scalable.
BioLizard has appointed Dr. Alexander Scheer as Chief Scientific Officer, adding 25+ years of translational R&D leadership across biotech and pharma. He will help scale BioLizard’s multi-omics and AI-driven strategy, strengthening work in biomarkers, precision medicine, and therapeutic innovation.
